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Abstract.
Some common systems modelling and simulation approaches for immune
problems are Monte Carlo simulations, system dynamics, discrete-event
simulation and agent-based simulation. These methods, however, are still
not widely adopted in immunology research. In addition, to our knowl-
edge, there is few research on the processes for the development of simu-
lation models for the immune system. Hence, for this work, we have two
contributions to knowledge. The rst one is to show the importance of
systems simulation to help immunological research and to draw the at-
tention of simulation developers to this research eld. The second contri-
bution is the introduction of a quick guide containing the main steps for
modelling and simulation in immunology, together with challenges that
occur during the model development. Further, this paper introduces an
example of a simulation problem, where we test our guidelines.
1 Introduction
Some important advances in immunology were facilitated by the joint work of
immunologists and mathematicians [1]. Many concepts existing in theoretical
immunology are the result of mathematical models. Inumerous existing models
in immunology are based on sets of ordinary dierential equations (ODEs) [2, 3].
This approach for immunology, however, in practice limits the modelling eort
to simpler dynamics involving fewer immune elements such as cells or molecules
and it only allows analysis at an aggregate level. Moreover, it is not trivial
to model problems involving individual localisation, memory of past events (or
states) and emerging properties mathematically [1]. Hence, systems simulation
emerged as a complement of mathematics that allows to overcome some of these
limitations. Moreover, systems simulation modelling methods are closer to the
natural description of the system, without the need of an in depth understanding
of mathematics [4].
Sauro et al. [5] debates the usefulness of simulation in contrast to reduction-
ism in biology. In reductionism, the dynamics of complex systems can be under-
stood from studying the properties of their parts [6]. In contrast to reductionism,
in holism (in its methodological version) the properties of the parts contribute to
our understanding of the whole, but the properties can only be fully understood
through the dynamics of the whole [6]. Systems simulation is, therefore, based
on holism. For biology, Sauro et al. [5] state that \reductionism has proven to be
a highly successful strategy and has enabled us to uncover the molecular details of
biological systems in unprecedented detail". The success of reductionist methods
raised some scepticism as to the need for alternative approaches, such as systems
biology. The challenge for simulation is, therefore, to generate novel insights that
cannot be uncovered just by looking at a phenomena using reductionism. Ex-
amples of successful simulation approaches that helped advance immunological
research were introduced in [7]. The models reviewed simulate interactions of im-
mune cells and chemical substances, humoral responses and drug testing. With
these simulations it is possible to observe emergent behaviour in the systems,
which is not feasible with reductionism.
As a rst objective of this study, therefore, we want to show that there is a
distinct place for simulation in the tool set that aids advances in immunology.
Moreover we want to show that there is a wide range of problems in immunology
to be tackled by computer scientists and simulation developers.
As there few examples on the methodology for constructing immune systems
simulations [8{10], the second objective is to introduce general guidances for con-
ducting simulation studies in immunology and outline the challenges that might
be encountered during the development of a simulation model. These guidances
adapted from the work developed by Robinson [11] for operational research, con-
sidering the characteristics observed in immune simulations. We complement the
current methodologies for constructing immune systems simulations by present-
ing a framework containing a life-cycle with the main steps to be followed by
any developer, independent of the simulation modelling method chosen.
The remainder of the paper is organized as follows. In Section 2 we review the
main characteristics of the simulation methods used in immunology. In Section 3
we present the main steps and propose a life-cycle for conducting a simulation
study for immune problems. In Section 4 we present a case study where we de-
velop a system dynamics simulation model from the steps outlined. In Section 5,
we present our conclusions and future work.
2 Simulation Methods
The choice of a modelling technique for a problem is driven by the resources avail-
able such as experimental data, an understanding of the mechanisms involved,
the hypothesis to be tested and the level of abstraction needed to test the hy-
pothesis. Once the conceptual model is dened, a simulation method needs to
be chosen. There is a wide spectrum of simulation methods used in immunology.
These methods are classied as static or dynamic, stochastic or deterministic,
continuous or discrete. These methods model the system using either top-down
or bottom-up perspectives. Static models help understand connections between
system components, without explicitly representing time [12]. Dynamic mod-
els aid in understanding dynamic implications and consequences over time of
a system structure [13]. Deterministic models do not contain any probabilistic
components. Stochastic models, on the other hand, consider random compo-
nents [14]. The characteristic of being continuous or discrete determine whether
time and variables of the model change continuously or discretely. For example
the age of an individual changes continuously in time, whereas the number of
immune cells that die with age is a discrete value. Top-down approaches focus on
the system at an aggregate level, while bottom-up approaches split the system
in individual parts that will interact giving rise to the behaviour of the system
as a whole [15].
Sauro et al. [5] mentions that the construction of models of biochemical and
cellular behaviour has been traditionally carried out through a bottom-up ap-
proach, which combines laboratory data and knowledge of a reaction network to
produce a dynamic model. This process, however, requires the reaction network
to be known and the possibility to carry out the various laboratory experiments.
Furthermore, the modelling relies on the fact that data from laboratory experi-
mentation matches real-world phenomena, which is not always correct. Samples
can be compromised during collection or during the experimentation process. In
addition, although bottom-up approaches are very useful for immunology, there
are circumstances where they can not be applied. Examples include when the
reaction network process is not well understood, or laboratory experiments are
known not to be able to reproduce the real-world reactions (for instance, given
the environmental dierences such as temperature). In addition, the authors
argue that \top-down modelling strategies are closer to the spirit of systems bi-
ology exactly because they make use of systems-level data, rather than having
originated from a more reductionist approach of molecular purication". The
conclusion reached in their study was that there is no best approach as it is
preferable to view them as complementary. Their ideas match other studies in
biology and other research areas, which investigate the merits of each approach
and their combination for simulation [16]. To our knowledge, the most com-
mon system simulation approaches for immunology are Monte Carlo simulation,
system dynamics, discrete-event simulation, cellular automata and agent-based
simulation.
Monte Carlo simulations [17] are largely used in molecular theoretical im-
munology. These techniques generate random numbers and observe that frac-
tion of the numbers that obey a certain property (of properties). These methods
are suitable for obtaining numerical solutions for problems as an alternative to
their analytical solution. The disadvantage of these methods are that they do
not provide information of how the elements of the system change during the
simulation (dynamics of the system). Instead, they focus on the determination
of the system outcome given a certain input, not taking time into account.
System dynamics (SD) is a top-down modelling technique that uses stocks,
ows and feedback loops as concepts to model the behaviour of complex systems
in a stock and ow diagram. It is an aspect of systems theory that is initially
applied in order to understand complex aggregate behaviours in industry [18].
Currently, SD is applied to any complex system characterized by interdepen-
dency, mutual interaction, information feedback and circular causality. System
dynamics simulation (SDS) is a continuous simulation for an SD model. It con-
sists of a set of ODEs that are solved for a certain time interval. These ODEs,
however, are implicit in the system's structure and the relationships between the
elements modelled can be established with experimental data. Some examples
of SD applied to the immune system are found in [19, 20].
Discrete-event simulation is also a top-down approach that models a system
as a set of entities being processed and evolving over time according to the
availability of resources and the triggering of events. The simulator maintains an
ordered queue of events [21]. Each event occurs at an instant in time and marks
a change of state in the system. It is process-oriented and the entities involved
are passive [11], with no pro-activity. The entities are individually represented
and can be tracked throughout the system simulation. The models are stochastic
and outputs usually represent average values [22]. Examples of applications for
the immune system are found in [23{25].
Cellular automata is a discrete model consisting of two main components. The
rst component is an innite regular grid of cells, which constitutes the universe
or space of the cellular automata. In computer simulations, however, due to
space limitations, the cellular automata space is predetermined and nite. The
second component is a nite automaton (or cell). Each cell from the grid contains
a nite number of states and a predened set of cells called neighbourhood.
The communication of a cell with other cells within its neighbourhood is local,
deterministic, uniform and synchronous [26]. Each cell is initialized with an initial
state at time t = 0. As time advances, the cells are updated according to a xed
rule, which is, in general, a mathematical function. This rule denes the next
state of each cell according to its current state and its neighbourhood states.
Examples of several applications for the immune system are found in [7].
Agent-based simulation is a technique that employs autonomous agents that
interact with each other [27]. The agents' behaviour is described by rules that de-
termine how they learn, interact with each other and adapt. The overall system
behaviour arises from the agents' individual dynamics and their interactions [21].
For immunology, it can amalgamate in vitro data on individual interactions be-
tween cells and molecules of the immune system to build an impression of the
system as a whole. Cellular automata and agent-based simulation have some
similarities such as individual rules and interactions between the individuals en-
tities. Moreover, both are bottom-up approaches capable of representing emer-
gent behaviour in the system. The entities in cellular automata, however, do not
have memory and only interact with individuals from the predened neighbour-
hood, as their location does not change. In agent-based simulation, on the other
hand, the agents are individual entities with memory and are capable to interact
with any other agent in the system. Several examples of agent-based models in
immunology are found in the european virtual human immune system project
(ImmunoGrid) [28].
By reviewing the simulation methods and some of their applications to im-
mune problems, such as those from [7, 23{25, 29], it is possible to outline the
benets of simulation to immunology and, therefore, achieve our rst objec-
tive of this work. Compared with real-world experimentation, simulation is time
and cost-eective. Most laboratory experiments are expensive and have to be in
agreement with ethical specications. Furthermore, in a simulation environment,
it is possible to systematically generate dierent scenarios, conduct and replicate
experiments.
In the following section we full our second research goal of this paper, which
is to introduce a descriptive guide for the development of a simulation model in
immunology and the challenges that might be encountered during this process.
These guidances are kept general and can be applied to all simulation methods
in immunology.
3 Steps in a Simulation Study
As there is not much done to established guidance to develop simulations for
the immune system, we studied those developed by [11] for simulation in op-
erational research problems and adapted them for simulations of the immune
system. The adaptation was performed by studying several simulations under
dierent approaches developed for the immune system, as mentioned in the pre-
vious section. In order to adapt the guidelines developed by [11], we observed the
similarities and dierences with operational research and outlined general steps
for building immune simulations. These steps represent a life-cycle of a simula-
tion and therefore the method we present is iterative. Furthermore, we discuss
the pitfalls that might be encountered during the process, as shown below. In
some of the steps, extra eorts specic to immunology were not added as we
believe they are generic for any type of simulation.
1. Dene the Objectives. Overall, the objectives are either to investigate
a theory or propose a \what-if" scenario with no concern to ethics restrictions.
The scenario proposed can either be based on experimental data or dened as
an intuition of what might happen in reality. Furthermore, there are also cases
where actual models do not match real-world experimentation and they need to
be further investigated (in a simulation model). In addition, new hypotheses and
research questions may be dened together with immunologists as simulation
goals. The objectives come from real-world observation. We assume, however,
that real-world observation and experimentation has been previously performed
by immunologists.
2. Describe the system. In this step, it is necessary to use documents
(immunology books and articles, transcripts of interviews with experts, etc.)
describing how the immune elements to be simulated work and interact. The
description of the system is based on knowledge acquired by theoretical work,
real-world observation and laboratory experimentation. Due to the complexity
of the elements and processes in the immune system, however, this knowledge
is scarce. The immune system is far from being fully fathomable, and the de-
scriptions found in literature are only partial representations and assumptions
of what occurs in reality.
3. Investigate existing theories and established models. In order to
build a new simulation model, it is common to look at the existing models
and investigate their hypotheses, objectives, validation process and limitations.
For some cases, these established models have somehow been validated against
experimental data. With this practice it is possible to build a new model as an
improvement of what has already been established in order to further investigate
a certain immune process.
4. Use experimental data. Currently, most simulation models are built
based on real-world observation and experimentation. There are some models,
however, where there is no data available (for example, when Jerne's network
theory was conceptualized [30]). These models are based purely on theoretical
assumptions with the purpose of providing more insights about what happens
in the real world. Furthermore, in the eld of immunology, the non-existence of
data can be due to the lack of understanding of a process, or a diculty or even
impossibility in collecting information with current technology. In other cases, a
hypothesis is rst formulated requiring experimental data to conrm it. There is,
therefore, the need to collect this data. For instance, Foan et al. [20] implemented
a system dynamics simulation of T cell subsets throughout a person's lifetime
based on an established mathematical model developed by Balcheva [31]. The
authors conclude that further validation of this model is necessary and so a
novel data set should be collected as there are arguably more specic markers
that could help to gain further insights from the model.
5. Build conceptual model. The conceptual model of a problem is an
abstraction intended to contain the principal aspects observed in the real world,
considering the necessary level of details [32]. In this step we formally dene the
model scope, the objectives previously outlined, the inputs and outputs and the
simplications. The process of creating a conceptual model evolves with decisions
regarding the model scope and level of detail [11]. The acceptance of the concep-
tual model should be agreed with immunologists. According to Ulgen et al. [33],
\rigorous validation procedure for the conceptual model is as important as the
verication and validation of the model because it saves time and redirects the
simulation developers in the right direction before time is wasted in the study".
Due to the limitations of a immune simulation, it is important to abstract the
relevant real-world features and build a simple model. According to Kotiadis and
Robinson [32], the importance of model abstraction \relies on the fact that there
is no need to model all that is known about the real problem. Simpler models are
developed and run faster, they are exible, require less data and results are eas-
ier to be interpreted". The nature of the immune problems thus implies that the
model should be developed in order to address a few objectives, within a limited
scope. The description of the system (and denition of the conceptual model)
should therefore focus on the parts of the immune system (scope, elements, in-
formation available, assumptions, hypotheses) relevant to achieve the simulation
goals. Daigle discusses the challenges of modelling immunology [34]. As it is a
eld in which information is still being gathered, simulations have to be updated
frequently to suit new ndings. Moreover, current computational resources and
modelling techniques are in development. It is still thereby impossible to repre-
sent computationally an entire pool of cells of a typical immune response (around
1012 cells). In addition, immunological systems are mostly hierarchical, involving
several layers and complex interactions between the elements of these layers.
6. Identify elements, parameters, aggregates, etc. already estab-
lished in theory and real-world data. The study of the conceptual model
provides a means to understand the problem and the best way to represent the
elements of the system. This stage inuences the choice of the most appropriate
simulation approach. For example, if the in the conceptual model it is established
the interactions of the simulation will occur at a cellular population level rather
than an individual cell level, this might indicate that a top-down simulation
approach would be more suitable to build the model.
7. Decide on the most appropriate simulation approach. This decision
is made based on the characteristics of the problems, the research questions to be
addressed, the scope, the level of aggregation and the experimental data avail-
able. Some of the most common approaches used in immunology are agent-based
modelling and simulation, discrete-event modelling and simulation, cellular au-
tomata and system dynamics. Cellular automata is used for problems involving
autonomous individual interactions within a neighbourhood placed in a lattice
and emergent behaviour. Agent-based simulation is suitable for problems involv-
ing autonomous individual behaviour, elements spacial localization, memory and
emergence. Discrete-event simulation tackles problems that are process-oriented,
which have passive individual entities and chronological sequence of events. Fur-
thermore, each event occurs at an instant in time and marks a change of state in
the system. It can be used for any experiment where there is no need for contin-
uous time. SD denes a system at a high level of aggregation and, therefore, it
should be used when the research question involves patterns of behaviours and
feed-back interactions between the aggregates. This approach is very useful to
simulate dynamics of populations and interactions between dierent populations
overtime. For example, interactions between tumours and populations of eector
cells, populations of viruses and T cells, etc.
8. Represent elements, parameters, etc. using the appropriate sim-
ulation approach. Once the simulation approach is chosen, the elements de-
ned in the conceptual model need to be translated into their correspondent
implementation used by each approach, for instance, stocks, ows, parameters
and information for SD or agents and rules for ABMS. This step is part of the
construction of the simulation model, dened in the next step.
9. Build the simulation model. This stage includes the development of
the computational implementation of the model in a simulation tool. The imple-
mentation is a software representation of the requisites dened in the conceptual
model. The computational model is the nal product to be used by the immu-
nologists.
10. Verify the model. The model verication is the process of ensuring that
the model design has been transformed into a computer model with sucient
accuracy [11].
11. Validate the model with existing theories and, if available, real-
world data. Validation ensures that the model is suciently accurate for the
purpose at hand. For immunology it is acknowledged that models are not in-
tended to be completely accurate for a number of reasons: (1) there is no real
world data to compare against, (2) there is little data, (3) real-world data is
inaccurate, (4) even if the data is accurate, the real world data is only a sample,
which in itself creates inaccuracy. Verication and validation are continuous and
iterative processes performed throughout the life cycle of a simulation study [11].
12. Experimental design. The experimental design improves the experi-
mentation process by the denition of sound experiments with trustworthy re-
sults. In this stage, the experimental factors that are most likely to lead to signif-
icant improvements are identied. This process is developed using data analysis,
expert knowledge, preliminary experimentation and sensitivity analysis.
13. Experimentation. Experimentation is conducted following the exper-
imental design guidelines. It can make use of multiple simulation replications;
interactive experimentation (observing the simulation and making changes to
the model to see the eects); batch experimentation (setting experimental fac-
tors and leaving the models to run for a pre-dened run length); comparing
alternatives (where there is a limited number of scenarios to be compared) and
search experimentation (when there is no predened number of scenarios).
14. Result Analysis. Plots and statistics are collected during the simula-
tion. The result analysis is the process that interprets results and the best way
to present them.
15. Report Findings. After results are interpreted, there is the need to
report the ndings from the simulations. For immunology, it can be new insights,
verication of a theory, etc.
16. Validate and add more requisites with immunologists. Build-
ing an immune simulation is an iterative process. Generally the model is built
together with immunologists, and, in every step of the framework, the model
elements should be veried with them.
The process of simulation is iterative, as shown in Figure 1. During the model
development, additional data might become available, which changes the sys-
tem description/objectives and impacts on every step of the process. Moreover,
as validation occurs throughout the whole process, if any of the stages is not
validated (data available, real world understanding and description, conceptual
model, computer model, experimental design, etc), there is the need to go back
and rethink the invalid state, which impacts on the subsequent steps.
4 Case Study
The objective of our case study is to exemplify how the steps dened previously
can be employed to help in the development of a simulation for the immune
system. The problem to be investigated is how the population of peripheral naive
T cells evolve during the course of an individual's lifetime. The development of
the simulation model is depicted below.
Fig. 1. Process of simulation study: the life cycle.
1. Dene Objectives. The simulation goal is concerned with establishing
an understanding of the peripheral naive T cell repertoire dynamics over time.
2. Describe the System. In the human body there is a type of white blood
cell, namely the naive T cell, which plays an important role in the immune system
by responding to new infections in the organism. Before an individual reaches
the age of 20, the set of naive T cells is sustained primarily from thymic output.
In middle age, however, there is a change in the source of naive T cells: as the
thymus involutes, there is a considerable shrinkage in its T cell output, which
means that new T cells are mostly produced by peripheral expansion. There is
also a belief that some memory T cells have their phenotype reverted back to
the naive proliferation cells type [35]. Furthermore, memory cells are originated
from active T cells.
3. Investigate existing theories and models. Immunologists found out
that thymic contribution in an individual are quantied by the level of a bio-
logical marker called `T cell receptors excision circle' (TREC). TREC is circular
DNA originated during the formation of the T-cell receptor. The percentage of T
cells possessing TRECs decays with shrinkage of thymic output, activation and
reproduction of naive T cells [35]. This means that naive T cells originating from
the thymus have a greater percentage of TREC than those originating through
other proliferation and with time there is a depletion of naive T cells from thy-
mus in the organism. There is an existing model proposed by Murray [35] that
investigates the thymic output and decay of these cells mathematically with the
use of an ODE system.
4. Experimental data. TREC data collected by immunologists is presented
by Murray et al. [35], which also develops an ODE system model for the dynamics
of peripheral naive T cells. Furthermore, the authors provided us with data on
active cells and total naive T cells in individuals with age ranging from 1 to 55
years. If we assume that this data has been validated by the immunologists and
expresses what occurs in reality, we can use this information for the continuation
of our investigations on naive cells from peripheral proliferation.
5. Conceptual model. The population dynamics of the model is shown
in Figure 2. We have four main populations of cells: naive from thymus (in
the gure naive), naive from proliferation, active cells and memory cells. Naive
and memory cells are sources of naive cells from proliferation. Active cells are
sources of memory cells. The scope of the simulation, therefore, is limited to the
dynamics of these four populations. The number of naive from thymus and active
cells are given by real-world data collected by immunologists. The conceptual
model and data used are the same as the those from the existing model proposed
by Murray [35]. The objective is to determine what are the dynamics of the naive
cells from peripheral proliferation with age under a systems simulation approach
dierent from the ODEs simulation. Another goal is to determine the rates in
which the naive cells from thymus and memory cells become naive cells from
proliferation; and the rates in which active cells become memory cells.
Fig. 2. Dynamics of Naive T cells.
6 and 7. Identify elements, parameters, etc. and decide on the most
appropriate simulation approach. As the investigations regard populations
dynamics at a high level of aggregation, as dened in the conceptual model, we
decided to build the simulation using the system dynamics approach, where the
aggregates will be each dierent cell population and the feedback loops are those
represented by the arrows in the conceptual model of gure 2.
8. Represent elements, parameters, etc. using the appropriate sim-
ulation approach. As stated before, system dynamics models consist of stock,
ows, information and feedback loops. The stocks of the simulation are the
variables that accumulate over time; ows modify the stocks by adding or sub-
tracting elements. For the simulation, therefore, the stocks will be the num-
ber of naive cells from proliferation and memory cells. The stock of naive cells
from proliferation is modied by ows such as addition of new cells from thy-
mus, peripheral proliferation and death, as shown in Figure 2 from the con-
ceptual model. The memory cells stock is changed by the ows: active cells
reversing into memory and memory cells death. Both naive and active cells are
represented in the simulation as look up tables. Moreover, parameters repre-
senting rates in which ows modify the stocks need to be incorporated. These
parameters are: NaiveThymusProliferationRate, NaiveProliferationRate,
NaiveProliferationDeathRate, MemoryToNPRate, MemoryDeathRate and
ReversionToMemoryRate.
9. Build the simulation model. The nal SD model implemented is shown
in Figure 3.
Fig. 3. SD built from naive T cells data.
In the gure, the stocks are represented by the box , the ow variables
are represented by the hourglass , ow , parameters and infor-
mation . Information indicates that the stock value is used in the ow
calculation. RealNaives and RealActives are look-up tables containing the ex-
perimental data.
9. Verify the model. As the model studied is quite simple, we veried
our implementation against the conceptual model. Further verication was per-
formed during the experimental stage.
10. Validate the model with existing theories and, if available, real-
world data. As we mentioned, the validation process is performed throughout
all simulation development. We validate our results against the data set provided
for the total number of naive T cells in the organism, as shown in the result
analysis (step 12).
11. Experimental design and experimentation. For this case study we
will run one experiment in which we adjust the parameters to t the original
data. The simulation was run for a period correspondent to sixty years.
12. Result Analysis and ndings. We calibrated the simulation parame-
ters against the data provided and the results obtained are shown in Figure 4(a).
Figure 4(b) shows the results obtained in [35]. For both approaches, the total
number of naive cells for the simulation are dierent for the rst eighteen years
and this dierence as well as the parameters obtained need further investigation
with immunologists. After twenty years, the numbers for the real data observed
and the outcomes obtained are very close. Moreover, it is possible to observe how
the population of naive cells from proliferation grows with time and is prevalent
in the total naive cells cohort after fty years.
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Fig. 4. Simulation results. For the SD simulation, the parameter values used are:
NaiveThymusProliferationRate = 0.025, NaiveProliferationDeathRate = 0.017, Mem-
oryToNPRate = 0.001, ReversionToMemoryRate = 0 and MemoryDeathRate = 0.05.
13. Validate and add more requisites with immunologists. Results
(and parameters calibration) validation needs to be done with immunologists, as
well as new requisites do be added in the simulation model. There is the need to
investigate whether the simulation models are informative and relatively accu-
rate. Further research also needs to be done to explain the outcome dierences
for both models.
5 Conclusions
Although there are examples showing the success of simulation aiding advances
in immunology, this set of methodologies is not popular among immunologists.
The overall objective of our research, therefore, is to outline the potential contri-
bution of simulation methods to help immunological studies and invite experts
(simulation developers, computer scientists, etc) to build solutions in this eld.
For this paper, we had two research goals. The rst goal was to show that there is
a distinct place for simulation in the tool set used by immunologists and present
the most common simulation approaches. As there are no general guidelines for
the development of immune simulations, our second objective was to introduce
our own guidances for conducting simulation studies in immunology and outline
the pitfalls that might be encountered during the development of a simulation
model. We achieved our rst objective by arguing that popular methodologies
used such as ODEs and reductionist methods have limitations that are overcome
by simulation. Moreover, we argued that for many simulation methods, the prob-
lem representation is closer to the systems natural description. For our second
goal, we studied several simulations using dierent approaches in the literature
and outlined their common features. This helped us to develop a simulation life-
cycle with several steps to be followed. These steps encompass common aspects
to be considered during the development of immune simulations, independent of
the simulation approach adopted. As future work we want to improve the life-
cycle introduced and develop a decision framework that further helps with the
choice of a simulation approach according to the problem presented. In addition,
we aim at making our set of guidances more specic according to the simulation
method used.
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